272 related articles for article (PubMed ID: 25680619)
1. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Lee AY; Lee CS; Butt T; Xing W; Johnston RL; Chakravarthy U; Egan C; Akerele T; McKibbin M; Downey L; Natha S; Bailey C; Khan R; Antcliff R; Varma A; Kumar V; Tsaloumas M; Mandal K; Liew G; Keane PA; Sim D; Bunce C; Tufail A;
Br J Ophthalmol; 2015 Aug; 99(8):1045-50. PubMed ID: 25680619
[TBL] [Abstract][Full Text] [Related]
2. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
[TBL] [Abstract][Full Text] [Related]
3. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
[TBL] [Abstract][Full Text] [Related]
4. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care.
Liew G; Lee AY; Zarranz-Ventura J; Stratton I; Bunce C; Chakravarthy U; Lee CS; Keane PA; Sim DA; Akerele T; McKibbin M; Downey L; Natha S; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Egan C; Johnston RL; Tufail A
Eye (Lond); 2016 Nov; 30(11):1462-1468. PubMed ID: 27419839
[TBL] [Abstract][Full Text] [Related]
5. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.
Schwartz R; Warwick A; Olvera-Barrios A; Pikoula M; Lee AY; Denaxas S; Taylor P; Egan C; Chakravarthy U; Lip PL; Tufail A;
Ophthalmol Retina; 2021 Aug; 5(8):e11-e22. PubMed ID: 33866023
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
7. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010.
Cohen SY; Dubois L; Ayrault S; Dourmad P; Delahaye-Mazza C; Fajnkuchen F; Nghiem-Buffet S; Quentel G; Tadayoni R
Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2499-503. PubMed ID: 23604514
[TBL] [Abstract][Full Text] [Related]
10. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
[TBL] [Abstract][Full Text] [Related]
11. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.
Fasler K; Moraes G; Wagner S; Kortuem KU; Chopra R; Faes L; Preston G; Pontikos N; Fu DJ; Patel P; Tufail A; Lee AY; Balaskas K; Keane PA
BMJ Open; 2019 Jun; 9(6):e027441. PubMed ID: 31230012
[TBL] [Abstract][Full Text] [Related]
12. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
14. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
15. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
[TBL] [Abstract][Full Text] [Related]
16. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
[TBL] [Abstract][Full Text] [Related]
17. The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.
Egan C; Zhu H; Lee A; Sim D; Mitry D; Bailey C; Johnston R; Chakravarthy U; Denniston A; Tufail A; Khan R; Mahmood S; Menon G; Akerele T; Downey L; McKibbin M; Varma A; Lobo A; Wilkinson E; Fitt A; Brand C; Tsaloumas M; Mandal K; Kumar V; Natha S; Crabb D;
Br J Ophthalmol; 2017 Jan; 101(1):75-80. PubMed ID: 27965262
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration.
Muether PS; Hoerster R; Hermann MM; Kirchhof B; Fauser S
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):453-8. PubMed ID: 22573410
[TBL] [Abstract][Full Text] [Related]
19. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Hata M; Tsujikawa A; Miyake M; Yamashiro K; Ooto S; Oishi A; Nakanishi H; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):221-7. PubMed ID: 24961698
[TBL] [Abstract][Full Text] [Related]
20. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration.
Rasmussen A; Bloch SB; Fuchs J; Hansen LH; Larsen M; LaCour M; Lund-Andersen H; Sander B
Ophthalmology; 2013 Dec; 120(12):2630-2636. PubMed ID: 23830760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
